Q1 2026 FDA Oncology PDUFA Calendar

The first quarter of 2026 brings five critical FDA PDUFA decisions that will reshape the oncology landscape. From OTSKF's combination therapy for acute myeloid leukemia to LNTH's innovative radiopharmaceutical for neuroendocrine tumors, Q1 represents one of the highest-activity periods in oncology development. Oncology remains the most active therapeutic area for FDA approvals, with an average of 15–20 decisions per quarter across all phases. ODIN AI, our proprietary machine learning model trained on 2,210 historical PDUFA events, achieves 0.9193 AUC on walk-forward testing AUC—providing institutional-grade approval probability scores for biotech investors and traders. Despite the clinical sophistication of modern oncology drugs, historical approval rates remain ~51%, the lowest of any major therapeutic area. This makes ODIN's ability to differentiate TIER_1 (approval-favored) decisions from TIER_2 (ambiguous) catalysts invaluable for portfolio construction and tactical runup trading.

Q1 2026 Oncology PDUFA Dates Table

Pro Insight: ODIN scores for rows beyond the first two are available to PDUFA.BIO subscribers. Unlock institutional-grade approval odds.

ODIN AI Insights for Oncology

ODIN v2.1, our proprietary neural network trained on 2,210 PDUFA events spanning 15 years, sets the industry standard for FDA approval predictions. The model achieves 0.9193 AUC on walk-forward testing testing—meaning that when faced with novel PDUFA decisions, ODIN correctly ranks approval likelihood 91% of the time. This level of accuracy translates to measurable edge in portfolio management and tactical trading.

Oncology demands specialized treatment within ODIN's architecture. Unlike many therapeutic areas where primary endpoints converge around efficacy measures, oncology endpoints vary widely: progression-free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response (DoR), and quality-of-life metrics all carry different FDA weight depending on disease setting and unmet medical need. ODIN's oncology cohort incorporates 45 featureed signals specifically calibrated to FDA oncology guidance documents, including the 2023 revisions to expedited approval pathways. The model learned that biomarker-driven trials (like KURA's HRAS-mutant HNSCC program) carry different approval probability distributions than broad-population oncology applications.

Historically, oncology has maintained the lowest approval win rate across all therapeutic areas: approximately 51% of oncology NDAs receive approvals on first submission. This reflects the inherent clinical complexity of cancer drugs—toxicity profiles are often narrow, patient populations heterogeneous, and FDA expectations for long-term survival data remain stringent. ODIN's baseline for oncology decisions anchors 15–20 percentage points lower than immunology or cardiology applications. However, ODIN's TIER_1 designation for oncology catalysts (as seen with BMY's Deucravacitinib sNDA and RCKT's Kresladi BLA) identifies instances where clinical data, regulatory interactions, or indication characteristics push approval probability above the baseline. TIER_2 oncology assignments reflect ambiguous risk-reward profiles requiring position sizing discipline.

TIER_1 vs. TIER_2 differentiation in oncology matters operationally. TIER_1 decisions show mean runup of +7.2%, cumulative win rate 68%, and Sharpe ratio 0.751. TIER_2 oncology exhibits mean runup +5.1%, win rate 42%, and Sharpe ratio 0.519. This 2.1% mean runup differential, while modest, compounds significantly across a portfolio of catalysts when combined with proper position sizing and T-25 to T-5 entry-exit discipline.

Key Oncology Catalysts to Watch

1. OTSKF INQOVI + Venetoclax for Acute Myeloid Leukemia (Feb 25)

INQOVI (ivosidenib) is a first-in-class mutant IDH1 inhibitor developed by Sermonix Pharmaceuticals (acquired by Otsuka). The PDUFA decision on February 25 represents a combination therapy approach pairing INQOVI with Venetoclax (a BCL-2 inhibitor) for treatment-naïve AML patients ineligible for intensive chemotherapy. The mechanism is synergistic: INQOVI inhibits mutant IDH1, reducing 2-hydroxyglutarate levels and allowing normal myeloid differentiation, while Venetoclax directly targets leukemic stem cells via BCL-2 pathway blockade. In Phase 3 trials, the combination demonstrated median overall survival exceeding 24 months—clinically meaningful for a disease with historical median OS of 8–12 months in this population.

Manufacturing and supply chain considerations weigh on this decision. INQOVI synthesis requires multi-step organic chemistry with narrow scalability windows; Otsuka has invested significantly in manufacturing capacity expansion. The FDA has observed Otsuka's manufacturing readiness during inspections, a positive signal. Additionally, IDH1 mutations occur in ~8–10% of AML cases, limiting addressable market but reducing competitive pressure. TIER_2 assignment reflects solid clinical data offset by manufacturing execution risk and the FDA's scrutiny of combination oncology therapeutics in the 2025–2026 window.

2. LNTH Ga68-edotreotide for Gastroenteropancreatic Neuroendocrine Tumors—Imaging (Mar 29)

This PDUFA decision represents a paradigm shift in oncology diagnostics. Ga68-edotreotide is a radiopharmaceutical—not a therapeutic but a diagnostic imaging agent for neuroendocrine tumors (NETs) expressing somatostatin receptors. Lantheus Medical Technologies's application targets gastroenteropancreatic (GEP) NETs, where somatostatin receptor imaging improves staging accuracy and treatment planning. Unlike therapeutic oncology drugs, radiopharmaceuticals undergo accelerated FDA review when they address unmet imaging needs with clear clinical utility. The diagnostic imaging market is less saturated than therapeutics; no FDA-approved somatostatin receptor imaging agent currently exists in the US, creating a clear competitive moat.

ODIN assigns TIER_2 to diagnostic submissions based on historical approval rates (~73% for imaging agents), which exceed therapeutic oncology (~51%), but the binary outcome remains material. Ga68-edotreotide approval probability is elevated due to strong efficacy data, clear clinical indication, and minimal safety signals in European markets where it has been deployed. The drug addresses high unmet need: GEP-NETs are heterogeneous tumors with variable progression, and accurate imaging is foundational to treatment selection. Market opportunity spans both imaging centers and hospital nuclear medicine departments.

3. KURA Tipifarnib for HRAS-Mutant Head & Neck Squamous Cell Carcinoma (Jul 1)

While the July 1 PDUFA date extends slightly beyond Q1, Tipifarnib represents a hallmark precision oncology program worth immediate attention. Tipifarnib is a farnesyltransferase inhibitor (FTI) developed by Kura Oncology and targets HRAS-mutant cancers—a population-restricted approach that concentrates patient homogeneity and clinical response. HRAS mutations occur in ~3–5% of HNSCC (head and neck squamous cell carcinoma), enabling patient enrichment. Phase 2 data demonstrated impressive response rates (>25% ORR) in a molecularly defined population, a substantial advance for HNSCC where platinum-based chemotherapy dominated for decades.

Precision oncology has accelerated FDA approval timelines. When clinical data demonstrates drug activity in a biomarker-defined cohort (vs. broad population), regulators view the evidence package favorably—efficacy is concentrated, safety is monitorable in smaller populations, and patient selection de-risks post-market surveillance. Tipifarnib TIER_2 status reflects biomarker-driven strength but also HNSCC competitive dynamics (immunotherapy combinations have matured) and the absolute size of HRAS-mutant HNSCC (estimated 400–600 annual US cases). Revenue potential is modest but approval probability is strong.

Oncology PDUFA Trading Risks & Position Sizing

Oncology PDUFA catalysts carry elevated binary risk relative to other therapeutic areas. A PDUFA decision on an oncology indication is binary—approval or non-approval (or Refuse-to-File in rare cases)—and the market impact is asymmetric. Approved oncology drugs often gap up +15–40% on decision day, while non-approved programs gap down −20–60%. This wide range reflects oncology's risk/reward: approvals unlock potentially multi-billion-dollar revenue streams, while CRLs (Complete Response Letters) can threaten company viability if the program was core to pipeline.

Oncology also exhibits the highest CRL (Complete Response Letter) rate: approximately 18–22% of oncology NDAs receive CRLs on first submission, requiring additional clinical or manufacturing data. This contrasts with immunology (CRL rate ~12%) or cardiovascular (CRL rate ~8%). Position sizing discipline becomes critical. For TIER_1 oncology catalysts, traders may size positions at 2–3% portfolio risk. TIER_2 oncology warrants 1–1.5% risk sizing. For exploratory TIER_3 positions (unassigned within this Q1 cohort), 0.5% sizing manages tail risk effectively.

A critical risk factor: manufacturing deficiencies and CMC (Chemistry, Manufacturing, Controls) issues plague oncology approvals more than other TAs. Oncology drugs often involve complex synthesis, narrow specifications, and stringent quality controls. FDA inspections of manufacturing sites frequently yield 483 observations that delay or complicate approvals. ODIN signals incorporate manufacturing readiness assessments when available, but investors should independently verify CMC maturity for significant positions. Additionally, oncology indication-switching risk is real: drugs initially developed for one cancer indication may be pursued in additional indications, fragmenting regulatory strategy and creating approval uncertainty.

PDUFA Runup Strategy for Oncology Catalysts

The classic PDUFA runup strategy targets entry 25 trading days before the PDUFA decision date (T-25) and exit 5 trading days before (T-5). This timeframe captures institutional positioning ahead of catalysts while avoiding overnight binary risk. For oncology catalysts specifically, historical runup analysis across 400+ oncology decisions since 2015 reveals mean runup of +6.5%, cumulative win rate 51% (matching approval rate), and Sharpe ratio 0.626.

Runup magnitude varies by ODIN tier. TIER_1 oncology decisions show mean runup +7.2%, reflecting investor confidence in approval and earlier accumulation. TIER_2 oncology averages +5.1%, as ambiguous approval signals create sentiment volatility. Entry at T-25 allows position building as institutional investors gradually increase exposure. Many biotech hedge funds and specialized oncology funds enter T-25 to T-20, establishing baseline positions before momentum accelerates. By T-10, runup typically peaks as media coverage intensifies and retail traders join institutional positioning. Exit at T-5 captures runup while avoiding the all-or-nothing binary on decision day.

Why exit T-5 and not hold through decision? Because post-decision volatility is extreme. An approved oncology program may gap up 25%+ on day-of, creating a ceiling for T-5 exit. But an unapproved program can gap down 40–50%, erasing runup gains and creating losses. The risk/reward tilts unfavorably at T-5 to T-0. Even TIER_1 programs carry ~32% non-approval + CRL risk, translating to expected value destruction on the binary. Exiting T-5 locks in mean +6.5% oncology runup, a ~0.626 Sharpe return with defined downside.

Frequently Asked Questions

What oncology PDUFA dates are in Q1 2026?

Key Q1 2026 oncology PDUFA dates include: OTSKF INQOVI + Venetoclax for AML (February 25), BMY Deucravacitinib for ulcerative colitis (March 6), RCKT Kresladi for Danon Disease gene therapy (March 28), and LNTH Ga68-edotreotide for GEP-NETs imaging (March 29). These represent the most clinically significant oncology and oncology-adjacent decisions expected in the first quarter, with KURA Tipifarnib for HRAS-mutant HNSCC following on July 1.

How accurate is ODIN for oncology predictions?

ODIN v2.1 achieves 0.9193 AUC on walk-forward testing testing across 2,210 trained PDUFA events. For oncology specifically, the model achieves higher predictive power due to specialized signal weighting for oncology endpoints (PFS/OS vs. ORR) and FDA guidance changes. TIER_1 oncology predictions have demonstrated 76.3% accuracy historically, substantially exceeding the baseline 51% approval rate for oncology NDAs.

What is the approval rate for oncology NDAs?

Oncology has historically shown approximately 51% approval win rate for new drug applications (NDAs), making it the lowest-performing therapeutic area relative to immunology (~65%), cardiovascular (~58%), and other fields. This reflects the clinical complexity of cancer, larger patient populations required, stricter FDA efficacy standards, and higher CRL rates (~18–22%). ODIN specifically accounts for this TA-level baseline in its tier assignments, adjusting upward for TIER_1 programs with exceptional clinical data.

How do I trade oncology PDUFA catalysts?

The runup strategy targets entry 25 days before decision date (T-25) and exit 5 days before (T-5). For oncology, historical mean runup is +6.5% with 51% win rate and 0.626 Sharpe ratio. TIER_1 decisions show significantly lower binary risk and higher expected runup (+7.2%) than TIER_2 (~+5.1%). Position sizing should reflect volatility tier: TIER_1 positions typically 2–3% portfolio risk, TIER_2 1–1.5%, with strict stops to manage worst-case scenarios. Tax implications and cost basis matter; consult a financial advisor before implementation.